Trial intelligence / Profile preview

VC005 vs tofacitinib in active ankylosing spondylitis

CTR20230360Phase 2Completed

Sponsor
Jiangsu Vcare PharmaTech Co., Ltd.
Start
Feb 2023
Modality
Small Molecules
Countries
1
01

Overview

A Phase 2 trial of VC-005 in ankylosing spondylitis (AS), sponsored by Jiangsu Vcare PharmaTech Co., Ltd.. Started Feb 2023; status: completed.

02

Drugs

VC-005
03

Conditions

ankylosing spondylitis (AS)

Beyond the preview

Go deeper on CTR20230360.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20230360.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call